target_chembl_id,pref_name,organism,target_type,protein_classification,activity_count,activity_types,min_activity_nM,max_activity_nM,median_activity_nM,known_drug_mechanisms,known_drugs,total_known_drugs
CHEMBL3309103,G-protein coupled estrogen receptor 1,Rattus norvegicus,SINGLE PROTEIN,,1,EC50,50118.72,50118.72,50118.72,0,,0
CHEMBL213,Beta-1 adrenergic receptor,Homo sapiens,SINGLE PROTEIN,,6937,"% Ctrl, % Inhibition of Control Agonist Response (Mean n=2), % Inhibition of Control Specific Binding (Mean n=2), % of Control Agonist Response (Mean n=2), % of control, % of inhibition, AC50, ACT, Activation, Activation (% of control), Activity, Agonist potency, Blockade, Bmax, Clinical reference, Contractile force, DR10, EC50, ED50, Efficacy, Emax, IA, IA50, IC50, ID50, Imax, Inhibition, Inhibition (% of control), Inotropic effect, Intrinsic activity, KA, KB, Kb, Kd, Ki, Kic, Log Ki, MA, Max stimulation, Mean fold stimulation, Selectivity, Selectivity ratio, pEC50, pIC50, pK, pKact, pKd",0.0,1000000000.0,5600.0,30,ATENOLOL; LEVOBETAXOLOL HYDROCHLORIDE; ACEBUTOLOL HYDROCHLORIDE; ESMOLOL HYDROCHLORIDE; OXPRENOLOL HYDROCHLORIDE,30
CHEMBL2107,C-X-C chemokine receptor type 4,Homo sapiens,SINGLE PROTEIN,,3538,"%max, Activity, EC, EC50, ED50, Efficacy, Emax, FC, IC50, IC90, Inhibition, Kb, Kd, Ki, Mean fold stimulation, Ratio, Ratio IC50, logIC50, logKi, pIC50, pKb, pKi",0.02,1000000000.0,382.0,8,PLERIXAFOR; MSX-122; BURIXAFOR; MOTIXAFORTIDE; BALIXAFORTIDE,8
CHEMBL5872,G-protein coupled estrogen receptor 1,Homo sapiens,SINGLE PROTEIN,,111,"Activity, EC50, Efficacy, IC50, Inhibition, Ki, Mean fold stimulation, T1/2",0.3,1620.0,11.0,0,,0
